Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2019 3
2020 1
2021 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Impact of Mutational Status and Prognostic Factors on Survival in Chronic Myelomonocytic Leukemia With Systemic Inflammation and Autoimmune Disorders.
Dussiau C, Dupuy H, Bidet A, Sauvezie M, De-Grande AC, Boureau L, Riviere E, Forcade E, Bonnet F, Dumas PY, Duffau P, Pigneux A, Viallard JF, Dimicoli-Salazar S, Lazaro E. Dussiau C, et al. Among authors: boureau l. Hemasphere. 2023 Feb 23;7(3):e847. doi: 10.1097/HS9.0000000000000847. eCollection 2023 Mar. Hemasphere. 2023. PMID: 36844177 Free PMC article. No abstract available.
Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis.
Guy A, Danaee A, Paschalaki K, Boureau L, Rivière E, Etienne G, Mansier O, Laffan M, Sekhar M, James C. Guy A, et al. Among authors: boureau l. Hemasphere. 2020 May 5;4(3):e364. doi: 10.1097/HS9.0000000000000364. eCollection 2020 Jun. Hemasphere. 2020. PMID: 32647794 Free PMC article. No abstract available.
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Rea D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX. Nicolini FE, et al. Among authors: boureau l. Clin Cancer Res. 2019 Nov 15;25(22):6606-6613. doi: 10.1158/1078-0432.CCR-18-3373. Epub 2019 Jul 10. Clin Cancer Res. 2019. PMID: 31292142 Clinical Trial.
[Accreditation strategy for rare somatic molecular abnormalities detected or quantified by polymerase chain reaction: GBMHM recommendations].
Sujobert P, Dulucq S, Alary AS, Etancelin P, Bouvier A, Boureau L, Chauveau A, Kosmider O, Flandrin P; Pour l’ensemble des auteurs de la session « Posters » sélectionnés pour le Challenge 180 secondes. Sujobert P, et al. Among authors: boureau l. Ann Biol Clin (Paris). 2019 Dec 1;77(6):681-684. doi: 10.1684/abc.2019.1498. Ann Biol Clin (Paris). 2019. PMID: 31859645 Free article. French.